Doug Giordano, Senior Vice President
Worldwide Business Development
Our operating unit structure promotes an entrepreneurial spirit, and gives each business unit the power and accountability to make decisions tailored to specific partners and customers in specific markets.
Uwe Schoenbeck, Chief Scientific Officer
External R&D Innovation
Partnerships are increasingly critical to Pfizer's research strategy. Thus Pfizer built External R&D Innovation (ERDI): a unique, externally-focused scientific team of high-profile PhDs / MDs embedded within Pfizer research groups to secure the right external alliances with biopharma and academic partners. ERDI provides a centralized hub for external partners as well as internal research and business leaders in the Idea to clinical POC space and partners closely with Pfizer BD and Legal teams to ensure effective transaction of deals.
Bob Smith, Senior Vice President
Business Development, Worldwide Research and Development, and Alliance Management
We have a broad portfolio that spans the entire spectrum of human and animal health, which opens us to considering a wide range of partnerships. One of the benefits of partnering with us is our dedicated alliance management group, which focuses on ensuring successful partnerships not just at the start, but throughout our relationships.
Barbara Dalton, Vice President
Pfizer Venture Investments
We invest in innovative emerging companies that have the potential to significantly advance healthcare through product development, technology advancement or service deployment.
Dana Hughes, Vice President
Integration and Operations Management Team
Using proprietary tools and practices, we support the Business Development Team, Business Units and Research Units — and their partners — with an efficient decision and integration effort. We work to improve deal success, operational stability and directly drive the most critical enterprise programs to assured success.
Bob Bagdorf, Vice President
Biopharmaceuticals Search & Evaluation
With a dedicated team of business development professionals aligned by therapeutic area, we work closely with our disease area leaders to formulate and execute external opportunity sourcing and assessment strategies to support our Business Units in the post-POC (proof-of-concept) space.